A study that evaluated different variables associated with immunotherapy response across different tumor types found that, among 36 variables, CD8+ T cell abundance was the most predictive of the response to immunotherapy across cancer types, followed by the TMB and the fraction of samples with high PD-1 gene expression (39). The gene discussed is CD8A; the disease is neoplasm.